荃信生物-B(02509.HK)发布中期业绩，收入2.06亿元 同比增长359.69%
Qyuns TherapeuticsQyuns Therapeutics(HK:02509) Jin Rong Jie·2025-08-15 14:21

Core Viewpoint - The company reported significant revenue growth and a substantial reduction in losses for the six months ending June 30, 2025, indicating a positive trend in financial performance [1] Financial Performance - The company achieved a revenue of RMB 206 million, representing a year-on-year increase of 359.69% [1] - Research and development expenses amounted to RMB 151 million, reflecting a year-on-year increase of 4.25% [1] - The net loss for the period was RMB 30.93 million, which is a decrease of 83.11% compared to the previous year [1] - The loss per share was RMB 0.13 [1]